Eastgate Biotech (ETBI) Stock Price
Eastgate Biotech Price
The stock trades about 2,900% above its 52-week low.
Eastgate Biotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Eastgate Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Eastgate Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Eastgate Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Eastgate Biotech Price |
|---|---|
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/3/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/19/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/15/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
| 6/2/2026 | 0.00 USD |
| 6/1/2026 | 0.00 USD |
| 5/29/2026 | 0.00 USD |
| 5/28/2026 | 0.00 USD |
| 5/27/2026 | 0.00 USD |
| 5/26/2026 | 0.00 USD |
| 5/22/2026 | 0.00 USD |
| 5/21/2026 | 0.00 USD |
| 5/20/2026 | 0.00 USD |
| 5/19/2026 | 0.00 USD |
| 5/18/2026 | 0.00 USD |
| 5/15/2026 | 0.00 USD |
| 5/14/2026 | 0.00 USD |
| 5/13/2026 | 0.00 USD |
| 5/12/2026 | 0.00 USD |
| 5/11/2026 | 0.00 USD |
| 5/8/2026 | 0.00 USD |
| 5/7/2026 | 0.00 USD |
| 5/6/2026 | 0.00 USD |
| 5/5/2026 | 0.00 USD |
| 5/4/2026 | 0.00 USD |
| 5/1/2026 | 0.00 USD |
| 4/30/2026 | 0.00 USD |
| 4/29/2026 | 0.00 USD |
| 4/28/2026 | 0.00 USD |
| 4/27/2026 | 0.00 USD |
| 4/24/2026 | 0.00 USD |
| 4/23/2026 | 0.00 USD |
| 4/22/2026 | 0.00 USD |
| 4/21/2026 | 0.00 USD |
| 4/20/2026 | 0.00 USD |
| 4/17/2026 | 0.00 USD |
| 4/16/2026 | 0.00 USD |
| 4/15/2026 | 0.00 USD |
| 4/14/2026 | 0.00 USD |
| 4/13/2026 | 0.00 USD |
| 4/10/2026 | 0.00 USD |
| 4/9/2026 | 0.00 USD |
| 4/8/2026 | 0.00 USD |
| 4/7/2026 | 0.00 USD |
| 4/6/2026 | 0.00 USD |
| 4/2/2026 | 0.00 USD |
| 4/1/2026 | 0.00 USD |
| 3/31/2026 | 0.00 USD |
| 3/30/2026 | 0.00 USD |
| 3/27/2026 | 0.00 USD |
| 3/26/2026 | 0.00 USD |
| 3/25/2026 | 0.00 USD |
| 3/24/2026 | 0.00 USD |
| 3/23/2026 | 0.00 USD |
| 3/20/2026 | 0.00 USD |
| 3/19/2026 | 0.00 USD |
| 3/18/2026 | 0.00 USD |
| 3/17/2026 | 0.00 USD |
| 3/16/2026 | 0.00 USD |
| 3/13/2026 | 0.00 USD |
| 3/12/2026 | 0.00 USD |
| 3/11/2026 | 0.00 USD |
| 3/10/2026 | 0.00 USD |
| 3/9/2026 | 0.00 USD |
| 3/6/2026 | 0.00 USD |
| 3/5/2026 | 0.00 USD |
| 3/4/2026 | 0.00 USD |
| 3/3/2026 | 0.00 USD |
| 3/2/2026 | 0.00 USD |
| 2/27/2026 | 0.00 USD |
| 2/26/2026 | 0.00 USD |
| 2/25/2026 | 0.00 USD |
| 2/24/2026 | 0.00 USD |
| 2/23/2026 | 0.00 USD |
| 2/20/2026 | 0.00 USD |
| 2/18/2026 | 0.00 USD |
| 2/17/2026 | 0.00 USD |
| 2/13/2026 | 0.00 USD |
| 2/12/2026 | 0.00 USD |
| 2/11/2026 | 0.00 USD |
| 2/10/2026 | 0.00 USD |
| 2/9/2026 | 0.00 USD |
| 2/6/2026 | 0.00 USD |
| 2/5/2026 | 0.00 USD |
| 2/4/2026 | 0.00 USD |
| 2/3/2026 | 0.00 USD |
| 2/2/2026 | 0.00 USD |
| 1/30/2026 | 0.00 USD |
| 1/29/2026 | 0.00 USD |
| 1/28/2026 | 0.00 USD |
| 1/27/2026 | 0.00 USD |
| 1/26/2026 | 0.00 USD |
| 1/23/2026 | 0.00 USD |
| 1/22/2026 | 0.00 USD |
| 1/21/2026 | 0.00 USD |
| 1/20/2026 | 0.00 USD |
| 1/16/2026 | 0.00 USD |
| 1/15/2026 | 0.00 USD |
| 1/14/2026 | 0.00 USD |
| 1/13/2026 | 0.00 USD |
| 1/12/2026 | 0.00 USD |
| 1/9/2026 | 0.00 USD |
| 1/8/2026 | 0.00 USD |
| 1/7/2026 | 0.00 USD |
| 1/6/2026 | 0.00 USD |
| 1/5/2026 | 0.00 USD |
| 1/2/2026 | 0.00 USD |
| 12/31/2025 | 0.00 USD |
| 12/30/2025 | 0.00 USD |
| 12/29/2025 | 0.00 USD |
| 12/26/2025 | 0.00 USD |
| 12/24/2025 | 0.00 USD |
| 12/23/2025 | 0.00 USD |
| 12/22/2025 | 0.00 USD |
| 12/19/2025 | 0.00 USD |
| 12/18/2025 | 0.00 USD |
| 12/17/2025 | 0.00 USD |
| 12/16/2025 | 0.00 USD |
| 12/15/2025 | 0.00 USD |
| 12/12/2025 | 0.00 USD |
| 12/11/2025 | 0.00 USD |
| 12/10/2025 | 0.00 USD |
| 12/9/2025 | 0.00 USD |
| 12/8/2025 | 0.00 USD |
| 12/5/2025 | 0.00 USD |
| 12/4/2025 | 0.00 USD |
| 12/3/2025 | 0.00 USD |
| 12/2/2025 | 0.00 USD |
| 12/1/2025 | 0.00 USD |
| 11/28/2025 | 0.00 USD |
| 11/26/2025 | 0.00 USD |
| 11/25/2025 | 0.00 USD |
| 11/24/2025 | 0.00 USD |
| 11/21/2025 | 0.00 USD |
| 11/19/2025 | 0.00 USD |
| 11/18/2025 | 0.00 USD |
| 11/17/2025 | 0.00 USD |
| 11/14/2025 | 0.00 USD |
| 11/13/2025 | 0.00 USD |
| 11/12/2025 | 0.00 USD |
| 11/11/2025 | 0.00 USD |
| 11/10/2025 | 0.00 USD |
| 11/7/2025 | 0.00 USD |
| 11/6/2025 | 0.00 USD |
| 11/5/2025 | 0.00 USD |
| 11/4/2025 | 0.00 USD |
| 11/3/2025 | 0.00 USD |
| 10/31/2025 | 0.00 USD |
| 10/30/2025 | 0.00 USD |
| 10/29/2025 | 0.00 USD |
| 10/28/2025 | 0.00 USD |
| 10/27/2025 | 0.00 USD |
| 10/24/2025 | 0.00 USD |
| 10/23/2025 | 0.00 USD |
| 10/22/2025 | 0.00 USD |
| 10/17/2025 | 0.00 USD |
| 10/16/2025 | 0.00 USD |
| 10/15/2025 | 0.00 USD |
| 10/14/2025 | 0.00 USD |
| 10/13/2025 | 0.00 USD |
| 10/10/2025 | 0.00 USD |
| 10/9/2025 | 0.00 USD |
| 10/7/2025 | 0.00 USD |
| 10/6/2025 | 0.00 USD |
| 10/3/2025 | 0.00 USD |
| 10/2/2025 | 0.00 USD |
| 10/1/2025 | 0.00 USD |
| 9/30/2025 | 0.00 USD |
| 9/29/2025 | 0.00 USD |
| 9/26/2025 | 0.00 USD |
| 9/25/2025 | 0.00 USD |
| 9/24/2025 | 0.00 USD |
| 9/23/2025 | 0.00 USD |
| 9/22/2025 | 0.00 USD |
| 9/19/2025 | 0.00 USD |
| 9/18/2025 | 0.00 USD |
| 9/17/2025 | 0.00 USD |
| 9/16/2025 | 0.00 USD |
| 9/15/2025 | 0.00 USD |
| 9/12/2025 | 0.00 USD |
| 9/11/2025 | 0.00 USD |
| 9/10/2025 | 0.00 USD |
| 9/9/2025 | 0.00 USD |
| 9/8/2025 | 0.00 USD |
| 9/5/2025 | 0.00 USD |
| 9/4/2025 | 0.00 USD |
| 9/3/2025 | 0.00 USD |
| 9/2/2025 | 0.00 USD |
| 8/29/2025 | 0.00 USD |
| 8/28/2025 | 0.00 USD |
| 8/27/2025 | 0.00 USD |
| 8/26/2025 | 0.00 USD |
| 8/22/2025 | 0.00 USD |
| 8/21/2025 | 0.00 USD |
| 8/20/2025 | 0.00 USD |
| 8/19/2025 | 0.00 USD |
| 8/18/2025 | 0.00 USD |
| 8/15/2025 | 0.00 USD |
| 8/14/2025 | 0.00 USD |
| 8/13/2025 | 0.00 USD |
| 8/12/2025 | 0.00 USD |
| 8/11/2025 | 0.00 USD |
| 8/8/2025 | 0.00 USD |
| 8/7/2025 | 0.00 USD |
| 8/6/2025 | 0.00 USD |
Eastgate Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Eastgate Biotech Income Statement, Balance Sheet, Cash Flow Statement
| EBITM USD |
|---|
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | -1.00 | -4.00 | -4.00 | -2.00 |
| – | – | – | – | – | – | – | – | -1.00 | -4.00 | -4.00 | -2.00 |
| – | – | – | – | – | – | – | – | – | 300.00 | – | -50.00 |
| 11.63 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Eastgate Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Eastgate Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Eastgate Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Eastgate Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Eastgate Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Eastgate Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Eastgate Biotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Eastgate Biotech business model & stock analysis
Eastgate Biotech SWOT Analysis
Strengths
1. Innovative Products: Eastgate Biotech Corp offers a range of unique and innovative biotechnology products, giving them a competitive edge in the market.
2. Strong Research and Development: The company has a dedicated team of scientists and researchers, consistently working on developing new products and improving existing ones.
3. Solid Financial Position: Eastgate Biotech Corp has a stable financial position, allowing them to invest in research, marketing, and growth opportunities.
Weaknesses
1. Limited Market Presence: The company currently has a limited market presence and brand recognition, which makes it challenging to compete with established competitors.
2. Reliance on Third-Party Suppliers: Eastgate Biotech Corp relies on third-party suppliers for key ingredients and materials, which can potentially disrupt the supply chain and impact product availability.
3. Lack of Diversification: The company's product portfolio is focused on biotechnology products only, lacking diversification into other industries or sectors.
Opportunities
1. Growing Demand for Biotechnology: The global biotechnology market is experiencing significant growth, providing Eastgate Biotech Corp with opportunities to expand its customer base.
2. Strategic Partnerships: Collaborating with established pharmaceutical companies or institutions can help Eastgate Biotech Corp leverage their expertise, widen its distribution network, and gain credibility.
3. Emerging Markets: Expanding into emerging markets where there is a rising demand for biotech products can help the company tap into new revenue streams.
Threats
1. Intense Competition: The biotechnology industry is highly competitive, with numerous players vying for market share. Eastgate Biotech Corp faces the risk of competitors launching similar or superior products.
2. Regulatory Challenges: The biotech industry is subject to stringent regulations and compliance requirements, which can pose hurdles and delays in product development and commercialization.
3. Technological Advancements: Rapid advancements in biotechnology and genetic engineering may render current products obsolete or less effective, necessitating continuous innovation and adaptation.
Eastgate Biotech Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Eastgate Biotech historical P/E ratio, EBIT multiple, and P/S ratio
Eastgate Biotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Eastgate Biotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Eastgate Biotech shareholder structure
| % | Name |
|---|---|
0.00000% |
Eastgate Biotech Beneficial Ownership Filings (SEC 13D/G)
Eastgate Biotech Executives and Management Board
3 members · avg. age 56 · 67 % women
Ms. Anna Gluskin (62)
Chief Executive Officer, Director · since 2012
300,000.00 USD
Ms. Rose Perri (49)
President, Treasurer, Secretary, Director · since 2015
Mr. Bill Abajian
Chief Operating Officer
Frequently asked questions about Eastgate Biotech
Eastgate Biotech Corp's business model revolves around the development and commercialization of innovative and advanced drug delivery systems. The company focuses on enhancing the oral absorption and bioavailability of existing and new drugs. By using their proprietary technologies, Eastgate Biotech Corp aims to improve the efficacy and safety of various pharmaceutical products, including those used in the treatment of cancer, cardiovascular diseases, and infectious diseases. With a strong emphasis on research and development, the company strives to provide practical solutions that ultimately benefit patients and healthcare professionals.
Eastgate Biotech Corp is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Eastgate Biotech Corp in the market include companies such as Johnson & Johnson, Pfizer, Novartis, Merck & Co., and GlaxoSmithKline.
Eastgate Biotech Corp. is a company specializing in the development and commercialization of innovative pharmaceutical and biotechnological products. Founded in 2009, Eastgate Biotech Corp. has been dedicated to creating groundbreaking solutions in the healthcare industry. With a focus on regenerative medicine, the company aims to improve the lives of patients by providing advanced treatment options for a wide range of diseases and conditions. With a strong research and development team, Eastgate Biotech Corp. has successfully developed several cutting-edge products and continues to explore new avenues in the field of biotechnology. As a leader in the industry, Eastgate Biotech Corp. strives to deliver high-quality, effective therapies that address critical medical needs.
Eastgate Biotech Corp has achieved several significant milestones. The company successfully developed a revolutionary insulin delivery system called "Transdermal Continuous Glucose Insulin Infusion" (TCGI) that offers an alternative method for diabetes management. Eastgate Biotech Corp also obtained global patents for TCGI, ensuring exclusivity in the market. Additionally, they have made considerable progress in clinical trials, demonstrating the safety and efficacy of their technology. Furthermore, Eastgate Biotech Corp secured strategic partnerships with renowned institutions and key stakeholders in the healthcare industry. These achievements highlight the company's commitment to innovation and improving the lives of individuals with diabetes.
Eastgate Biotech Corp is primarily present in the United States. The company has its headquarters in Toronto, Canada, but its operations and focus are centered in the United States, particularly in the field of innovative pharmaceuticals and biotechnology. With a strong presence in the US market, Eastgate Biotech Corp aims to leverage its expertise and technologies to advance healthcare solutions and contribute to the well-being of individuals across the country.
Eastgate Biotech Corp represents a commitment to innovation, advancing healthcare solutions, and improving patients' lives. With a focus on biotechnology, the company is dedicated to developing cutting-edge therapeutic solutions, such as its oral insulin drug, to tackle prevalent diseases like diabetes. Eastgate Biotech Corp aims to provide effective, convenient, and patient-friendly alternatives to traditional injectable treatments. By prioritizing research and scientific advancements, the company strives to make a significant impact in the medical field. With its emphasis on forward-thinking solutions, Eastgate Biotech Corp consistently works towards improving healthcare outcomes and meeting global healthcare challenges head-on.
Converted at the current exchange rate, the Eastgate Biotech share trades at 0.00 EUR (0.00 USD).
The Eastgate Biotech Corp is a publicly traded company that focuses on the development and marketing of new, innovative products in biotechnology. The company's business model is based on three main areas: the development of dietary supplements, medical products, and the manufacturing of diagnostic test kits. In the field of dietary supplements, Eastgate Biotech Corp has developed unique products that have been made based on peptides, polysaccharides, and other natural active ingredients. These products have been specifically designed for a variety of applications, including improving physical performance, supporting weight loss, increasing mental clarity and concentration, as well as combating inflammation and pain. In the medical field, Eastgate Biotech Corp has developed various products that contribute to improving people's health. These include products specifically designed to support the immune system, promote bone and joint health, treat infections, and reduce inflammation. Another area of the company's business is the manufacturing of diagnostic test kits. These kits are used for various applications, including diagnosing infectious diseases, cardiovascular diseases, autoimmune diseases, and cancer. The test kits are easy to use and can be utilized by medical professionals as well as patients in a home setting. One of the greatest advantages of Eastgate Biotech Corp is the close connection between research and production. The company has its own research and development department that continuously develops new products. Collaborations with partners in the field of science and industry also contribute to the development of new innovations. Products that have proven successful in research are manufactured in their own production facilities. This enables Eastgate Biotech Corp to quickly bring products to market and produce them on a large scale. This also allows for customizations or the development of new products based on customer demands. Another advantage of Eastgate Biotech Corp is the use of natural active ingredients to ensure product safety and effectiveness. This allows the company to meet vegetarian or vegan standards and reach a larger and growing target audience. Overall, it can be said that Eastgate Biotech Corp is a successful company with a promising business model. With continuous research and development of new products, the use of natural active ingredients, and the ability to quickly and efficiently meet customer needs, the company has established a solid foundation for further growth and long-term success.
The revenue cannot currently be calculated for Eastgate Biotech.
The profit cannot currently be calculated for Eastgate Biotech.
The P/E ratio cannot be calculated for Eastgate Biotech at the moment.
The P/S cannot be calculated for Eastgate Biotech currently.
The Eulerpool Quality Score for Eastgate Biotech is 2/10.
The ISIN of Eastgate Biotech is US2772531008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Eastgate Biotech is ETBI. The ticker symbol is used to trade Eastgate Biotech shares on the stock exchange.
Eastgate Biotech paid dividends every year for the past 0 years.
Eastgate Biotech is assigned to the '—' sector.
The dividends of Eastgate Biotech are distributed in USD.
Eastgate Biotech stock
Eastgate Biotech Peer Group
Eastgate Biotech Ticker
Eastgate Biotech FIGI
All fundamentals and in-depth analysis of Eastgate Biotech
Our stock analysis for Eastgate Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eastgate Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.